Stian Kildal

All filings by Stian Kildal on record concern OncoZenge AB, in the capacity of chief executive. We count 5 filings; the first trade dates from 28 March 2025 and the latest from 18 September 2026.

No open-market sale appears; the market trades are 3 purchases worth €61k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant.

Half of the purchases are above €14k and half below. As a share of market capitalisation, the median purchase stands at 0.16%, based on 3 purchases. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The newest entry dates from 26 September 2026: a transaction of €99k, in OncoZenge AB. The latest purchase dates back some time: it was published 345 days ago, on 28 November 2025. Typically, a trade is published a median of 1 day after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.